Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man

A H Kleine1, J F Glatz, F A Van Nieuwenhoven

  • 1Department of Physiology, University of Limburg, Maastricht, The Netherlands.

Insights

Heart fatty acid-binding protein (H-FABP) is a more suitable early indicator for acute myocardial infarction (AMI) than CK-MB or alpha-HBDH. H-FABP levels rise significantly within 3 hours of AMI onset, aiding faster diagnosis.

Area of Science:

  • Biochemistry
  • Cardiology
  • Clinical Diagnostics

Background:

  • Acute myocardial infarction (AMI) diagnosis relies on detecting cardiac biomarkers.
  • Current biomarkers like CK-MB and alpha-HBDH have limitations in early detection.
  • Heart fatty acid-binding protein (H-FABP) is a potential early diagnostic marker.

Purpose of the Study:

  • To evaluate the diagnostic utility of H-FABP for early detection of AMI.
  • To compare the release kinetics of H-FABP with established cardiac enzymes (CK-MB, alpha-HBDH).

Main Methods:

  • Development of a sensitive sandwich ELISA for human H-FABP quantification in plasma.
  • Measurement of plasma H-FABP, CK-MB, and alpha-HBDH levels in AMI patients.
  • Comparison of biomarker levels against established normal thresholds and time of symptom onset.

Main Results:

  • H-FABP levels significantly elevated within 3 hours post-AMI, exceeding normal thresholds.
  • Peak H-FABP levels observed at 4.1 hours, compared to 8.4 hours for CK-MB and 25 hours for alpha-HBDH.
  • H-FABP detected above threshold in 18/22 patients within 3.5 hours, versus 9/22 for CK-MB and 6/22 for alpha-HBDH.

Conclusions:

  • H-FABP is released rapidly and substantially from the heart following myocardial infarction.
  • H-FABP demonstrates superior sensitivity and earlier detection capability for AMI compared to CK-MB and alpha-HBDH.
  • H-FABP is a promising biomarker for early diagnosis of acute myocardial infarction.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...